(RTTNews) - Biotechnology company BriaCell Therapeutics Corp. (BCTX, BCT.V) announced Wednesday positive overall survival data of its Phase 2 clinical study of Bria-IMT in combination with an immune check point inhibitor (CPI) in late stage metastatic breast cancer.
The median overall survival of 15.6 months is reported in Phase 2 Bria-IMT study patients treated in combination with immune checkpoint inhibitor. The OS of 15.6 months compares favorably with 6.7-9.3 months reported for similar patients in the literature.
These patients are being treated with the same Bria-IMT formulation currently being used in BriaCell's ongoing Phase 3 pivotal study in metastatic breast cancer.
This represents a substantial improvement over BriaCell's 13.4 months median OS previously reported in December 2023.
The Phase 2 study enrolled 54 heavily pre-treated metastatic breast cancer patients who were treated with the Bria-IMT regimen and an immune checkpoint inhibitor. Of these 54 patients, 37 were treated with the Phase 3 formulation and 25 of these were treated post-COVID when full study activities resumed.
This data represents an additional six months of follow-up of the survival data presented at the San Antonio Breast Cancer Symposium in December 2023.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
